BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16303002)

  • 1. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.
    Funch DP; Walker AM; Schneider G; Ziyadeh NJ; Pescovitz MD
    Am J Transplant; 2005 Dec; 5(12):2894-900. PubMed ID: 16303002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
    Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
    Malouf MA; Chhajed PN; Hopkins P; Plit M; Turner J; Glanville AR
    J Heart Lung Transplant; 2002 May; 21(5):547-54. PubMed ID: 11983544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M; Husain S; Famure O; Li Y; Kim SJ
    Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG; Tan MYQ; Quak SH; Aw MM
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B; Riella LV; Dierickx D
    Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
    Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients.
    Keay S; Oldach D; Wiland A; Klassen D; Schweitzer E; Abruzzo LV; Kumar D; Bartlett S
    Clin Infect Dis; 1998 Mar; 26(3):596-600. PubMed ID: 9524829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
    Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
    Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
    Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients.
    Funch DP; Brady J; Ko HH; Dreyer NA; Walker AM
    Recent Results Cancer Res; 2002; 159():81-8. PubMed ID: 11785847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.
    Gao SZ; Chaparro SV; Perlroth M; Montoya JG; Miller JL; DiMiceli S; Hastie T; Oyer PE; Schroeder J
    J Heart Lung Transplant; 2003 May; 22(5):505-14. PubMed ID: 12742411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation.
    Green M; Reyes J; Webber S; Rowe D
    Transpl Infect Dis; 2001 Jun; 3(2):97-103. PubMed ID: 11395975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.